Related Experiment Videos
Diazepam binding inhibitor (DBI): a peptide with multiple biological actions
1Fidia-Georgetown Institute for the Neurosciences, Georgetown University School of Medicine, Washington, D.C. 20007.
Life Sciences
|January 1, 1991
Summary
Diazepam binding inhibitor (DBI) peptides interact with GABA-A receptors and mitochondrial receptors, influencing neurosteroid production and GABAA receptor function. These interactions explain DBI
Area of Science:
- Neuroscience
- Endocrinology
- Molecular Biology
Background:
- Diazepam binding inhibitor (DBI) is a polypeptide found in the brain and periphery.
- DBI and its metabolites, ODN and TTN, are distributed in neurons and glial cells.
- DBI is also present in peripheral steroidogenic tissues like the adrenal cortex and testes.
Purpose of the Study:
- To explore the neurobiological actions of DBI and its processing products.
- To investigate the role of DBI in neurosteroidogenesis.
- To understand the mechanisms underlying DBI's effects on GABAA receptors.
Main Methods:
- Isolation of DBI from rat brain.
- Distribution analysis of DBI in neurons, glial cells, and peripheral tissues.
- Assessing the effect of DBI and its metabolites on mitochondrial benzodiazepine receptors (MBRs).
Main Results:
- DBI binds to GABAA receptors and MBRs.
- MBR stimulation facilitates steroid production in peripheral tissues and brain glial cells.
- Neurosteroids produced in the brain modulate GABAA receptor function.
- DBI and fragments inhibit insulin release and bind acyl-CoA.
Conclusions:
- DBI's neurobiological effects are mediated by interactions with GABAA receptors and MBRs.
- DBI modulates neurosteroidogenesis, impacting brain and peripheral functions.
- DBI acts as a precursor for biologically active peptides with diverse actions.